Lexicon Pharmaceuticals, Inc.

Merck Sharp + Dohme Corp.

Other

Lexicon Genetics Corporation

Lexicon Pharmaceutical Inc.

Zhi-Cai Shi

Alexander Pasternak

Shawn P Walsh

Zhicai Wu

Haiming Zhang

Wenxue Wu

Ramanaiah C Kanamarlapudi

Ravi P Nargund

Dong-Ming Shen

Danqing D Feng

Haifeng Tang

Lin Yan

Songnian Lin

Dmitri A Pissarnitski

Christina B Madsen-Duggan

Ahmet Kekec

Pei Huo

Barbara A Pio

Jinlong Jiang

Dooseop Kim

Matthew Mangzhu Zhao

Joseph A Kozlowski

Yongxin Han

Paul E Finke

Kun Liu

Wensheng Yu

Jeffrey John Hale

Hong Shen

Hongjun Zhang

Shuwen He

Iyassu Sebhat

Fa-Xiang Ding

Liangqin Guo

Thomas H Graham

Spencer David Kimball

Guoqing Li

Purakkattle J Biju

Derun Li

Helen Y Chen

Harry R Chobanian

Cynthia Anne Fink

Yongqi Deng

Abdelghani Achab

Yan Guo

Xavier Fradera

Timothy A Blizzard

Ashok R Tunoori

Haihong Jin

Ying Wang

Arokiasamy Devasagayaraj

Chengmin Zhang

Brian Cato

Hartmuth C Kolb

Jessica Frie

Yuping Zhu

Hugh Alfred Burgoon, Jr

Yingjun Mu

Iain Fraser Pickersgill

Aurash Shahripour

Qinghong Fu

Brett A Marinelli

Lakshama Samala

Zhi-Min Wang

Cullen Cavallaro

Joseph Barbosa

Qinglin Pu

Kevin Michael Belyk

Timothy Allen Blizzard

Zhiqiang Guo

Qingyun Liu

Gerard M McGeehan

Cangming Yang

Wensheng Liu

Min Shu

Timothy A Cernak

Paul F Richardson

Reynalda K DeJesus

Heidi Theis

Laxma Reddy Kolla

Alexander Gontcharov

Ronald Dale Ferguson

Esther Y Kim

Brent Marinelli

Jessica L Frie

Kevin M Belyk

Lianqin Guo

Reynalda K Dejesus

Disclosed herein is a compound of formula (I), or a pharmaceutically acceptable salt thereof: Formula (I). Also disclosed herein are uses of the compounds disclosed herein in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising a compound disclosed herein. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. 

Substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Insulin dimers and insulin analog dimers that act as partial agonists at the insulin receptor are disclosed.

Insulin receptor partial agonists

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and conditions associated with excessive salt and water retention.

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

This invention relates to compounds of Formula I having the following general structure:Z&#x2014;Y&#x2014;(CH)&#x2014;R&#x2014;(CH)&#x2014;Y&#x2014;Zwherein R represents a fused bicyclic or spirocyclic aliphatic diamine and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Compounds of structural formula I are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Prolylcarboxypeptidase inhibitors

This invention relates to compounds of Formula I-VI having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Inhibitors of the Renal Outer Medullary Potassium channel

This invention relates to compounds of Formula I having the following general structure: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Compounds of structural formula (I) are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Spiropiperidine prolylcarboxypeptidase inhibitors

Compounds of formula I are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and/or manage diseases and disorders: 

4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use

Compounds of formulae I and II are disclosed, as well as compositions comprising them and methods of their use to treat, prevent and manage serotonin-mediated diseases and disorders: 

Tryptophan hydroxylase inhibitors

Compounds of structural formulas I-1 and I-2 are inhibitors of prolylcarboxypeptidase (PrCP). The compounds of the present invention are useful for the prevention and treatment of conditions related to the enzymatic activity of PrCP such as abnormal metabolism, including obesity; diabetes; metabolic syndrome; obesity related disorders; and diabetes related disorders. 

Growing community of inventors

Monmouth Junction, NJ, United States of America

Zhi-Cai Shi